Diffuse Large B-Cell Lymphoma — Trials

Diffuse Large B-Cell Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 355
Recruiting: 190
Ph III recruiting: 16
Growth YoY: −8.8%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (177)

clinicaltrialsPublishedShowing 1–50 of 58 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05600686	Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma	active not recruiting	Phase 2	24	University of California, DavisOTHER	1	Sep 28, 2026	clinicaltrials
NCT03463057	The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL(HO151DLBCL)	active not recruiting	Phase 2	109	Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER